Evaluation of a Burkholderia Pseudomallei Outer Membrane Vesicle Vaccine in Nonhuman Primates  by Petersen, Hailey et al.
1877-282X © 2014 Elsevier B.V. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
Selection and peer-review under responsibility of the 7th Vaccine Conference Organizing Committee.
doi: 10.1016/j.provac.2014.07.007 
Available online at www.sciencedirect.com
ScienceDirect
7th Vaccine & ISV Congress, Spain, 2013 
Evaluation of a Burkholderia pseudomallei Outer Membrane 
Vesicle Vaccine in Nonhuman Primates 
Hailey Petersena, Wildaliz Nievesa, Kasi Russell-LodriguebChad J. Roya,b, Lisa A. 
Moricia*
aTulane University School of Medicine, New Orleans LA  70112, USA 
bTulane National Primate Research Center, Covington LA 70433, USA 
Abstract 
Burkholderia pseudomallei (Bps)is the causative agent of melioidosis and is endemic in regions of northern 
Australia and Southeast Asia. Bps is inherently resistant to multiple antibiotics and is considered a potential 
biological warfare agent by the U.S. DHHS. Therefore, effective vaccines are necessary to prevent natural infection 
and to safeguard against biological attack with this organism. In our previous work we have shown that 
immunization with naturally derived outer membrane vesicles (OMVs) from Bps provides significant protection 
against lethal aerosol and systemic infection in BALB/c mice. In this work, we evaluated the safety and 
immunogenicity of escalating doses of OMV vaccine in rhesus macaques. We show that immunization of rhesus 
macaques with Bps OMVs generates humoral immuneresponses to protective protein and polysaccharide antigens 
without any associated toxicity or reactogenicity. These results lay the groundwork for evaluation of protective 
efficacy of the OMV vaccine in the nonhuman primate model of melioidosis. 
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1. Background 
Bps is a Gram-negative, facultative-intracellular bacterium and the causative agent of melioidosis. Infection with 
Bps can manifest as acute septicemia, pneumonia and/or chronic disease and is associated with significant morbidity 
and mortality. Bps is naturally resistant to multiple antibiotics and there is currently no approved vaccine against the 
organism.Vaccine strategies against Bps includeinactivated whole cell preparations, live-attenuated strains, purified 
polysaccharides, glycoconjugates, and protein subunits, amongst others, but none have demonstratedlong term 
protection and sterilizing immunity in animal models.Outer membrane vesicles (OMVs) are non-replicating 
particles secreted by Gram-negative bacteria, such as Bps, that range between 50-250 nm in diameter. OMVs are 
enriched in protein, polysaccharide, and lipid microbial components, including potential immunogens, 
andcanfacilitate antigen presentation to both B and T cells. OMVsthus represent a multivalent, acellular vaccine 
platform with a potential forincreased safety and enhanced protection against melioidosis.Our previous studies have 
shown that Bps OMVs provide protection in an inhalational model of melioidosis in mice.1 We evaluated the safety 
and immunogenicity of escalating doses of OMV vaccine in rhesus macaques in order to advance the OMV vaccine 
for testing in a large animal model. We show that immunization of rhesus macaques with Bps OMVs 
generateshumoralimmune responseswithout any associated toxicity or reactogenicity. 
2. Materials and Methods 
Preparation of OMV vaccine.  B. pseudomallei strain 1026b (BEI Resources) was grown in LB broth at 37°C until 
late log phase (16–18 hr). The intact bacteria were pelleted by centrifugation at 6,000×g for 10 min at 4°C, and the 
supernatant was removed and filtered through a 0.22 μm polyethersulfone (PES) filter (Millipore) in order to 
remove any remaining bacteria or large bacterial fragments. To ensure the supernatant was free of viable bacteria, 1 
mL of supernatant was streaked onto PIA agar and incubated 48–72 hrs at 37°C. OMVs were harvested by slowly 
adding 1.5 M solid ammonium sulfate (Fisher Scientific) while stirring gently and incubated overnight at 4°C. The 
OMVs were harvested by centrifugation at 11,000×g for 20 min at 4°C. The resulting pellet, consisting of crude 
vesicles, was resuspended in 60% sucrose (Fisher Scientific) in 30 mM Tris-HCl pH 8.0,  filter sterilized through a 
0.22 μm PES filter and layered at the bottom of a centrifuge tube. A sucrose gradient was prepared by slowly 
layering 55%, 50%, 45%, 40%, and 35% sucrose in 30 mM Tris-HCl pH 8.0(w/v) over the crude OMV preparation. 
Membrane vesicles were collected by ultracentrifugation at 165,000×g for 3 hr at 4°C. Equal fractions were 
removed sequentially from the top and stored at 4°C. To determine the purity of the fractions, 500 μl of each was 
precipitated with 20% (w/v) Tri-chloroacetic acid (TCA). The resulting pellet was resuspended in 10 μl phosphate 
buffered saline (PBS) and 10 μl Laemmli loading buffer (Bio-Rad), boiled for 10 min and loaded onto an SDS-
PAGE polyacrylamide gel (4–20% Mini Protean, Bio-Rad) run at 200 V. The working OMV preparation was 
recovered by pooling the peak fractions (those containing the least amount of insoluble fragments and contaminants) 
in 30 mM Tris-HCl pH 8.0followed by centrifugation at 165,000×g for 3 hr at 4°C. The resulting pellet, containing 
OMVs, was then washed and resuspended in LPS-free water. OMVs were quantified with a Bradford Protein Assay 
(Bio-Rad). 
Purified Bps OMVs are negatively stained with 1% uranyl acetate and were imaged by transmission electron 
microscopy (TEM)to visually confirm their presence and purity. Purified Bps OMVs range in size from 50-250 nm 
in diameter and are spherical, double membrane structures with an electron dense center.Purified OMV preparations 
are free of extracellular debris and flagella (Figure 1). 
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Figure 1. Purified Bps outer membrane vesicles. Final preparations of OMVs were negatively stained with1% uranyl acetate, and then 
visualized using TEM. Bar indicates500nm. 
OMV immunization of nonhuman primates.Four male, age- and weight-matched, Indian rhesus macaques 
(Macacamulatta) were usedinthis study. Two animals (IN71 and II81) were immunizedsubcutaneously (SC) with 
Bps OMVs admixed with 400 μg CpG oligodeoxynucleotides (ODN)2395 (InvivoGen). Two animals (HM73 and 
DJ17) were immunized with CpG ODN only and served as controls. Immunizations were performed on days 0, 28, 
and 56.OMV immunizations were administered using a dose escalation regimen with the first dose containing 25μg, 
the second dose 50μg, and the third dose 100 μg of OMV. The experimental design in shown in Figure 2.
Blood was obtained prior to immunization (pre-immune) and 4 weeks after each immunization to measure 
humoral immune responses to OMV vaccination. OMV-, lipopolysaccharide (LPS)-, and capsular polysaccharide 
(CPS)-specificplasmaIgG were measured by ELISA usingmicrotiter plates coated with purified preparations of 
OMV, LPS, or CPS. Safety and toxicity of the OMV vaccine was monitored by complete blood chemistry and by 
daily health examinations. 
Figure 2.  Experimental design to evaluate BpsOMV vaccine safety and immunogenicity in rhesus macaques. Animals were immunized with 
escalating doses of Bps OMVs admixed with CpG ODN (n=2) or CpG ODN alone (n=2). 
3. Results 
3.1Assessment of OMV vaccine safety in rhesus macaques 
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To assess safety of the OMV vaccine formulation, blood chemistry measurements were obtained in OMV-
immunized and control macaques. Blood was obtained pre-vaccination and at24, 48, and 72 hr after the first 
immunization and prior to each booster dose.An increase in blood neutrophil numbers was noted 24 hr after OMV 
immunization, but neutrophil counts returned to normal range by 72 hr post- immunization. Clinical measurements 
indicated no changes in liver or kidney function throughout the study(Table 1). The vaccine injection site was also 
closely examined over the course of immunizations and no erythema, swelling, or necrosis was observed at any 
time.  
3.2Assessment of humoral immune responses elicited by OMV immunization of rhesus macaques 
Antibody responses were examinedover the course of the OMV prime-boost-boost immunization. NHPs immunized 
withBps OMVs produced significantly higher titers of OMV-specific IgG compared to pre-immune sera and sera 
Table 1. Blood chemistry measurements in OMV-immunized and control-immunized macaques. Blood was collected from animals at indicated
time points and analyzed using a CBC chemistry panel.IN71, II81 – OMV-immunized; HM73, DJ17 – controls. 
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obtained from control-immunized animals after three immunizations.LPS-and CPS-specific IgG were also measured 
to determine if humoral immune responses were generated against these known protective antigens.  LPS-and CPS-
specific serum IgG titers were significantly elevated in OMV-immunized verses controls animals. The LPS-specific 
IgG response accounted for nearly half of the overall OMV-specific IgG response, while the CPS-specific antibody 
accounted for approximately 1/5 of the OMV-specific IgG. Taken together, these data demonstrate that Bps OMVs 
are highly immunogenic and stimulate humoral immunity in immunized rhesus macaques.  
Figure 3. Bps OMV-specific IgG in plasma of immunized NHPs. OMV-, LPS-, and CPS-specific plasma IgG isshown for pre-immune samples 
as well as samples obtained after a primary immunization with 25µg, a boost with 50µg, and a second boost with 100µg of OMV vaccine
admixed with CpG. Control animals received 400µg of CpG only at each immunization point.  IN71, II81 – OMV-immunized; HM73, DJ17 – 
controls.
4. Conclusion 
This work demonstrates the safety and immunogenicity of a Bps OMV vaccine in nonhuman primates.No 
adverse reactions or toxicity were observed in any macaque that received up to 100 μg OMV indicating that the 
vaccine is safe at doses equivalent or higher to that previously used in humans2. OMV immunization produced high 
titers of OMV-, LPS-, and CPS-specific plasmaIgG.The data generated here are encouraging because antibodies 
directed against OMV, LPS, and CPS are protective in small animal models of melioidosis3. This suggests that the 
protein and polysaccharide-specific antibody observed in OMV-immunized macaques may confer 
protectionduringexperimental infection with Bps.Future studies are warranted to evaluate the protective efficacy of 
the OMV vaccine in a nonhuman primate model of melioidosis. 
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